Why the study?
Does pharmacogenomic profiling predict response to heart failure therapy?
Does pharmacogenomic profiling predict response to heart failure therapy?
While data is currently limited, pharmacogenomics (such as ADRB1 and CYP2D6 profiling) holds potential for personalizing heart failure therapy.
ADRB1 and CYP2D6 merit prospective outcome trials in HF β-blocker therapy; leaves open routine pharmacogenomic-guided care.
BACKGROUND: Heart failure (HF) and multiple HF-related phenotypes are heritable. Genes implicated in the HF pathophysiology would be expected to influence the response to treatment. METHODS: We conducted a series of systematic literature searches on the pharmacogenetics of HF therapy to assess the current knowledge on this field. RESULTS: Existing data related to HF pharmacogenomics are still limited. The ADRB1 gene is a likely candidate to predict response to β-blockers. Moreover, the cytochrome P450 2D6 coding gene (CYP2D6) clearly affects the pharmacokinetics of metoprolol, although the clinical impact of this association remains to be established. CONCLUSION: Given the rising prevalence of HF and related costs, a more personalized use of HF drugs could have a remarkable benefit for patients, caregivers and healthcare systems.
No takes yet. Share an insight, caveat, or question.
Mottet et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: